Aurion Biotech

Aurion Biotech company information, Employees & Contact Information

Explore related pages

Aurion Biotech email format Aurion Biotech management contacts

Related company profiles:

Aurion Biotech is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care.

Company Details

Employees
85
Founded
-
Address
Seattle, Wa 98110, Us
Industry
Biotechnology
Website
https://aurionbiotech.com
Keywords
jobs.
HQ
Seattle, WA
Competitors
Alnylam Pharmaceuticals, Garuda Therapeutics, Vertex Pharmaceuticals, Amgen, Bristol Myers Squibb, Alcon, AbbVie, Delix Therapeutics, Beam Therapeutics, Sarepta Therapeutics.
Looking for a particular Aurion Biotech employee's phone or email?

Aurion Biotech Questions

News

Aurion Biotech Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025 - Business Wire

Aurion Biotech Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025 Business Wire

User - FinancialContent

User FinancialContent

Aurion Biotech: Cell Therapy AURN001 Improves Vision in Patients with Corneal Endothelial Disease - 2 Minute Medicine

Aurion Biotech: Cell Therapy AURN001 Improves Vision in Patients with Corneal Endothelial Disease 2 Minute Medicine

Aurion Biotech Evaluating Combination Cell Therapy Product AURN001 as Alternative to Corneal Transplant in Phase 1/2 ABA-1, CLARA Clinical Trial - CGTLive®

Aurion Biotech Evaluating Combination Cell Therapy Product AURN001 as Alternative to Corneal Transplant in Phase 1/2 ABA-1, CLARA Clinical Trial CGTLive®

Aurion Biotech completes dosing of all subjects in Phase 1/2 CLARA trial - Ophthalmology Times

Aurion Biotech completes dosing of all subjects in Phase 1/2 CLARA trial Ophthalmology Times

Aurion Biotech Expands Its Leadership Team - citybiz

Aurion Biotech Expands Its Leadership Team citybiz

Aurion Biotech Announces Positive Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction - Business Wire

Aurion Biotech Announces Positive Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction Business Wire

Aurion Biotech’s ABA-1 Clinical Trial for Corneal Edema Cell Therapy AURN001 Doses First Canadian Patient - CGTLive®

Aurion Biotech’s ABA-1 Clinical Trial for Corneal Edema Cell Therapy AURN001 Doses First Canadian Patient CGTLive®

Aurion Biotech Expands Leadership Team, Promoting Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer - Business Wire

Aurion Biotech Expands Leadership Team, Promoting Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer Business Wire

Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months - Business Wire

Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months Business Wire

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease - Business Wire

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease Business Wire

Aurion Biotech CEO Greg Kunst Named Ernst & Young 2024 Entrepreneur of the Year Mountain West Region - Business Wire

Aurion Biotech CEO Greg Kunst Named Ernst & Young 2024 Entrepreneur of the Year Mountain West Region Business Wire

Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001 - Business Wire

Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001 Business Wire

Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea - Business Wire

Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea Business Wire

Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer - Business Wire

Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer Business Wire

Greg Kunst Appointed CEO of Aurion Biotech - Business Wire

Greg Kunst Appointed CEO of Aurion Biotech Business Wire

Aurion Biotech Appoints Jonathan Sparks, JD, PhD as Chief Legal Officer - Business Wire

Aurion Biotech Appoints Jonathan Sparks, JD, PhD as Chief Legal Officer Business Wire

Aurion Biotech Wins Prestigious Prix Galien Startup Award - Business Wire

Aurion Biotech Wins Prestigious Prix Galien Startup Award Business Wire

Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application - Business Wire

Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Business Wire

Aurion Biotech Appoints Arnaud Lacoste as Chief Scientific Officer - citybiz

Aurion Biotech Appoints Arnaud Lacoste as Chief Scientific Officer citybiz

Daniela Drago Joins Aurion Biotech as Chief Regulatory Officer - Business Wire

Daniela Drago Joins Aurion Biotech as Chief Regulatory Officer Business Wire

Aurion Biotech Names Edward Holland, MD, Chief Medical Advisor - Business Wire

Aurion Biotech Names Edward Holland, MD, Chief Medical Advisor Business Wire

About Us - FinancialContent

About Us FinancialContent

Aurion Biotech Appoints Professor Shigeru Kinoshita, MD, PhD, to Its Medical Advisory Board - Business Wire

Aurion Biotech Appoints Professor Shigeru Kinoshita, MD, PhD, to Its Medical Advisory Board Business Wire

Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial - FinancialContent

Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial FinancialContent

Aurion Biotech Announces Strategic Investments in Manufacturing - FinancialContent

Aurion Biotech Announces Strategic Investments in Manufacturing FinancialContent

Silicon Valley - FinancialContent

Silicon Valley FinancialContent

Companies like Aurion Biotech

Amgen logo - Similar company to Aurion Biotech

Amgen

35.77K
AbbVie logo - Similar company to Aurion Biotech

Abbvie

57.01K
Delix Therapeutics logo - Similar company to Aurion Biotech

Delix Therapeutics

29
Garuda Therapeutics logo - Similar company to Aurion Biotech

Garuda Therapeutics

20
Alnylam Pharmaceuticals logo - Similar company to Aurion Biotech

Alnylam Pharmaceuticals

2.58K
Sarepta Therapeutics logo - Similar company to Aurion Biotech

Sarepta Therapeutics

1.37K
Bristol Myers Squibb logo - Similar company to Aurion Biotech

Bristol Myers Squibb

38.47K
Alcon logo - Similar company to Aurion Biotech

Alcon

26.80K
Vertex Pharmaceuticals logo - Similar company to Aurion Biotech

Vertex Pharmaceuticals

6.09K
Beam Therapeutics logo - Similar company to Aurion Biotech

Beam Therapeutics

557

Top Aurion Biotech Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant